PMID- 37201406
OWN - NLM
STAT- MEDLINE
DCOM- 20230616
LR  - 20230616
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 120
DP  - 2023 Jul
TI  - Fucoidan mitigates gastric ulcer injury through managing inflammation, oxidative 
      stress, and NLRP3-mediated pyroptosis.
PG  - 110335
LID - S1567-5769(23)00658-6 [pii]
LID - 10.1016/j.intimp.2023.110335 [doi]
AB  - This study aimed to elucidate the gastro-protective effect of fucoidan against 
      ethanol-induced gastric ulcer mediated via NLRP3-induced pyroptosis as an 
      underlying mechanism, not yet assessed in prior research. Forty-eight male Albino 
      mice were divided into six groups: Group I (normal control), group II 
      (Ulcer/ethanol control), group III (Omeprazole + ethanol), group IV (fucoidan 
      25 mg + ethanol), group V (fucoidan 50 mg + ethanol) and group VI (fucoidan 
      only). Fucoidan was administered orally for seven consecutive days followed by 
      ulcer induction by a single oral dose of ethanol. Using colorimetric analysis, 
      ELISA, qRT-PCR, histological assessment, and immunohistochemical studies, the 
      results revealed that ethanol-induced ulcer exhibited an ulcer score of 
      42.5 +/- 5.1 and a significant increase (p < 0.05) in malondialdehyde (MDA), 
      nuclear factor kappa B (NF-kappaB), and interleukin 6 (IL-6) with a significant 
      decrease in the gastro-protective mediators, prostaglandin E2 (PGE2), superoxide 
      dismutase (SOD) and glutathione (GSH), accompanied with an increase in NLRP3, 
      interleukin 1beta (IL-1beta), interleukin 18 (IL-18), caspase 1, caspase 11, gasdermin 
      D, and toll-like receptor 4 (TLR4), compared with the normal control. 
      Pre-treatment with fucoidan showed a comparable result with omeprazole. 
      Additionally, pre-treatments elevated the levels of the gastro-protective 
      mediators and lessened oxidative stress, relative to the positive control 
      findings. Conclusively, fucoidan has a promising gastro-protective role by 
      inhibiting inflammation and pyroptosis.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Selim, Hend Mostafa
AU  - Selim HM
AD  - Biochemistry Department, Faculty of Pharmacy, Tanta University, Tanta 31527, 
      Egypt.
FAU - Negm, Walaa A
AU  - Negm WA
AD  - Department of Pharmacognosy, Faculty of Pharmacy, Tanta University, Tanta 31527, 
      Egypt.
FAU - Hawwal, Mohammed F
AU  - Hawwal MF
AD  - Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 
      4545, Saudi Arabia.
FAU - Hussein, Ismail A
AU  - Hussein IA
AD  - Department of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy (Boys), 
      Al-Azhar University, Cairo 11884, Egypt.
FAU - Elekhnawy, Engy
AU  - Elekhnawy E
AD  - Pharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, 
      Tanta 31527, Egypt.
FAU - Ulber, Roland
AU  - Ulber R
AD  - Institute of Bioprocess Engineering, Rheinland-Pfalzische Technische Universitat 
      Kaiserslautern-Landau, Gottlieb-Daimler-Strasse 49, 67663 Kaiserslautern, Germany.
FAU - Zayed, Ahmed
AU  - Zayed A
AD  - Department of Pharmacognosy, Faculty of Pharmacy, Tanta University, Tanta 31527, 
      Egypt; Institute of Bioprocess Engineering, Rheinland-Pfalzische Technische 
      Universitat Kaiserslautern-Landau, Gottlieb-Daimler-Strasse 49, 67663 
      Kaiserslautern, Germany. Electronic address: ahmed.zayed1@pharm.tanta.edu.eg.
LA  - eng
PT  - Journal Article
DEP - 20230516
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 9072-19-9 (fucoidan)
RN  - GAN16C9B8O (Glutathione)
RN  - KG60484QX9 (Omeprazole)
RN  - 3K9958V90M (Ethanol)
RN  - 0 (NF-kappa B)
SB  - IM
MH  - Mice
MH  - Animals
MH  - Male
MH  - *Stomach Ulcer/chemically induced/drug therapy/pathology
MH  - NLR Family, Pyrin Domain-Containing 3 Protein/metabolism
MH  - Ulcer/metabolism
MH  - Pyroptosis
MH  - Gastric Mucosa
MH  - Oxidative Stress
MH  - Inflammation/metabolism
MH  - Glutathione/metabolism
MH  - Omeprazole/therapeutic use/pharmacology
MH  - Ethanol/metabolism
MH  - NF-kappa B/metabolism
OTO - NOTNLM
OT  - Ethanol
OT  - Fucoidan
OT  - Gastro-protective
OT  - Inflammation
OT  - NLRP3
OT  - Pyroptosis
OT  - Ulcer
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/05/19 01:04
MHDA- 2023/06/16 06:42
CRDT- 2023/05/18 18:07
PHST- 2023/02/20 00:00 [received]
PHST- 2023/04/28 00:00 [revised]
PHST- 2023/05/10 00:00 [accepted]
PHST- 2023/06/16 06:42 [medline]
PHST- 2023/05/19 01:04 [pubmed]
PHST- 2023/05/18 18:07 [entrez]
AID - S1567-5769(23)00658-6 [pii]
AID - 10.1016/j.intimp.2023.110335 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2023 Jul;120:110335. doi: 10.1016/j.intimp.2023.110335. Epub 
      2023 May 16.